• In the SMC base case OS for first-line ipilimumab and first-line DTIC were modelled using a three-part curve fit ( Figure 3 ). This accounts for the distinctive survival profile observed for participants of the CA184-024 trial, the pooled chemotherapynaïve dataset and the MDX010-20 trial.
• The three-part curve comprised of: a) Up to 2 years: Kaplan-Meier data from the CA184-024 trial. b) Year 2 to 5: Parametric curve fit to trial data. c) Year 5 onwards: Parametric curve fit to long-term registry data from the American Joint Committee on Cancer (AJCC). 6 • This approach is in line with the SMC resubmission for secondline ipilimumab (779/12) 7 , follows the NICE Decision Support Unit model selection algorithm 8 and was recognised as appropriate by the Evidence Review Group for the first-line ipilimumab NICE submission. 9
COST-EFFECTIVENESS ANALYSIS OF IPILIMUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE MALIGNANT MELANOMA IN SCOTLAND Background
• The treatment options available for unresectable advanced (Stage III or IV) melanoma are limited and, prior to the recent recommendation of ipilimumab and vemurafenib, standard care in Scotland consisted primarily of dacarbazine (DTIC), which has never shown a significant survival benefit. [1] [2] [3] -Since April 2013, ipilimumab is recommended in Scotland for second-line treatment for advanced melanoma and is currently being assessed by the Scottish Medicines Consortium (SMC) as a first-line treatment having recently been approved for use across all lines by the National Institute of Health and Care Excellence (NICE).
-Since December 2013, vemurafenib is recommended in Scotland for first-line treatment for BRAF mutation-positive advanced melanoma only.
• There is a broad evidence base for the use of ipilimumab in advanced melanoma, demonstrating the potential for long-term survival from data from 4,846 patients, including data showing patients surviving up to 10 years, from multiple clinical trials and real-world data. 4 • As of November 2014, ipilimumab is recommended in Scotland as a first-line treatment based on the presented analysis for ipilimumab which compares its cost-effectiveness to treatment with vemurafenib and DTIC.
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Presented 
Objectives
We undertook a cost-utility analysis of ipilimumab versus vemurafenib and DTIC for previously-untreated advanced (unresectable or metastatic) melanoma patients. 
Results
• In the SMC base case analysis it was assumed that patients receive ipilimumab second-line after DTIC and vemurafenib in line with Scottish clinical practice.
-The base case incremental cost-effectiveness ratio (ICER) for ipilimumab compared with DTIC followed by ipilimumab was £31,481 per QALY gained (incl. the confidential discount for ipilimumab), see Table 3 .
-The ICER for ipilimumab compared with vemurafenib followed by ipilimumab fell into the south-west quadrant of the costeffectiveness plane.
-Ipilimumab alone compared with the sequence 'vemurafenib followed by ipilimumab' is associated with lower costs but also lower QALYs and LYs (as one fewer line of treatment is given).
-This results in an ICER of £126,482 per QALY gained (incl. the confidential discounts for ipilimumab and vemurafenib), and vemurafenib followed by ipilimumab is not cost-effective compared with ipilimumab alone.
Conclusion
• First-line ipilimumab treatment for melanoma is cost-effective, and as a first-line option it would expand clinician choice, enabling selection of the most appropriate therapy for patients depending on their disease characteristics and BRAF mutation status.
• The conclusion that ipilimumab is cost-effective was confirmed in scenarios using multiple potential clinical trial data sources. 
Key Points
1.An economic model was constructed to assess the cost effectiveness of ipilimumab as first-line treatment in Scotland. An 'area under the curve' approach was used.
2.The decision problem was modelled as a treatment sequencing model, incorporating ipilimumab as a second-line treatment option after DTIC and vemurafenib.
3.The model is parameterised by OS and PFS data from clinical trials.
4.Patient quality of life was modelled based on analyses of patient-level trial data from the CA184-024 trial, in which utility is estimated based on time to death.
5.Cost and resource use data were taken from the same sources as the previous appraisal for second-line ipilimumab for consistency, with costs expressed in 2013 reference year and from a Scottish perspective. 
£126,482
Key: BSC, best supportive care; DTIC, dacarbazine; ICER, incremental cost-effectiveness ratio; LY, life year; QALYs, quality-adjusted life years; SW, south-west. Note: † ICERs in the southwest quadrant mean that the comparator treatment is less costly and less effective. Key: BSC, best supportive care; DTIC, dacarbazine; ICER, incremental cost-effectiveness ratio; LY, life year; QALYs, quality-adjusted life years; SW, south-west. Note: † ICERs in the southwest quadrant mean that the comparator treatment is less costly and less effective. 
£269,865
Key: BSC, best supportive care; DTIC, dacarbazine; ICER, incremental cost-effectiveness ratio; LY, life year; QALYs, quality-adjusted life years; SW, south-west. Note: † ICERs in the southwest quadrant mean that the comparator treatment is less costly and less effective.
Key: DTIC, dacarbazine; OS, overall survival.
Key: DTIC, dacarbazine; OS, overall survival.
Methods

Structure
• A cost-utility model (Figure 1 ) was built to assess the costeffectiveness of ipilimumab for the first-line treatment of advanced melanoma patients in Scotland, adapted from a model submitted to the NICE.
• The model adopted the perspective of the Scottish National Health Service (NHS) and comprised four health states in the ipilimumab treatment arm: first-line treatment, best supportive care (BSC), terminal care and death; and five states in the vemurafenib and DTIC arms: first-line treatment, second-line ipilimumab, BSC, terminal care and death.
• These treatment sequences reflect the fact that vemurafenib is not recommended for second-line treatment, and DTIC is not an effective treatment, and is often substituted at second-line for a range of alternative treatments that make up BSC.
• The model used a weekly cycle length with a time horizon of 40 years.
• Costs and quality-adjusted life years (QALYs) were discounted at 3.5% per annum.
• The approach taken to model the OS of BRAF mutation-positive patients treated first line with vemurafenib is based on analyses submitted to NICE by Roche Products Ltd in support of the technology appraisal of vemurafenib. 10 This consisted of piecewise curves (which have been reconstructed based on available data) with some amendments to update the OS curve and make it more consistent with the requirements for this evaluation.
• The piecewise curve for vemurafenib was comprised of the following components: a) Up to 14 months: Kaplan-Meier data from the BRIM-3 vemurafenib trial.11 b) Between 14 and 46 months: Three sections of constant monthly risks. c) From 46 months onwards: Parametric curve fit to AJCC registry data. d) Furthermore, the BRIM-3 vemurafenib OS curve was adjusted to account for the effect of considerable use of second-line ipilimumab via a tunnel state methodology. e) BRIM-3 vemurafenib and DTIC OS curves were covariateadjusted to account for differences in patient baseline characteristics (between BRIM-3 and CA184-024).
• Figure 4 presents the final predictions for OS for ipilimumab, vemurafenib and DTIC used in the base case analysis.
• Further details on the adjustment methodology used can be found at ISPOR (Tuesday pm, 11 th November 2014) in poster PRM80.
• It has to be noted that for ipilimumab this OS prediction is very conservative as data from >1,800 ipilimumab-treated patients, across different doses and treatment regimens, show an OS plateau developing around Year 3 and extending to Year 10, with approximately 20% of advanced melanoma patients surviving up to 10 years (whereas the prediction in Figure 4 assumes only about 10% of patients surviving at 10 years).
• As the mode of action of ipilimumab means that the criteria for tumour progression may not accurately reflect patients' response to ipilimumab (response to ipilimumab can cause tumour enlargement that may be misinterpreted as progression) 12 , the progression-free survival (PFS) curves for ipilimumab are used differently in deriving the transition probabilities for the movement of patients between health states. The transition from first-line treatment with ipilimumab is calculated as the minimum of two competing risks: the risk of clinical disease progression and the risk of entering the last 12 months of life. As such, where there is a sustained response to ipilimumab, patients will transition to become eligible for second-line treatment more slowly, in line with actual treatment practice.
Costs
• Cost and resource use data (Table 2) were taken from the same sources as the previous appraisal for second-line ipilimumab for consistency, with costs expressed in 2013 reference year and from a Scottish perspective.
• Table 4 presents the scenario using the data for the 3mg/kg ipilimumab dose from the MDX010-20 trial, adjusted for difference in key prognostic characteristics to provide a more accurate estimate of the efficacy of the 3mg/kg at first line, using adjusted Kaplan-Meier data.
• Results are consistent with the CA184-024 trial analysis with slightly lower predicted OS for ipilimumab and therefore higher ICER.
• Table 5 shows the scenario using the chemotherapy-naïve patient data, pooled across multiple Phase II and III trials of ipilimumab. In this scenario, the DTIC and vemurafenib arms were modelled in the same way as they were in the base case.
• Results are consistent with the CA184-024 trial analysis with slightly higher predicted OS for ipilimumab and therefore lower ICER.
• It is worth noting that available ipilimumab long-term data, with up to 10 years follow-up, demonstrate greater survival at 5 and 10 years than is modelled 4 , suggesting that the model underestimates the potential survival gain from adopting treatment with ipilimumab, and thus the ICERs presented are overestimated.
• Higher LYs gained and QALYs gained in the vemurafenib arm are attributed to the use of second-line ipilimumab. This effect is however not seen in the ipilimumab arm, as second-line vemurafenib is not recommended in Scotland.
• Patients are assumed to spend the last month (4 weeks) of their life in terminal care. The 4-week duration of terminal care is in accordance with Scottish clinical expert advice. 5 • The transitions of patients between health states are based on trial data and are calculated using a two-step process. Firstly, movement between lines of treatments and the proportion of patients who die is calculated. Secondly, the proportion of patients on each line of treatment is adjusted to account for the proportion of patients expected to be receiving terminal care.
Health-related quality of life
• In an analysis of directly-observed patient-level quality-of-life data from the CA184-024 trial (converted to utilities), progression status was found not to impact quality of life. The most meaningful correlation identified was between quality of life and time to death.
• Given this correlation, patients' quality of life is modelled based on analyses of patient-level trial data from the CA184-024 trial, in which utility is estimated based on time to death (Table 1 ).
• Based on the overall survival (OS) outcomes of the model, patients are distributed across six quality-of-life health substates, which are applicable to all lines of treatment (shown in Figure 2 ), each with an associated utility value depending on six time-to-death intervals.
• The regression model including both time to death and treatment effect was used as the model base case for all treatments.
• The active treatment decrement for ipilimumab was also applied to the vemurafenib cohort in the model, based upon the assumption that the adverse event (AE) profiles of the two drugs are comparable; similar proportion of patients experience serious AEs in the clinical trials. No decrement was applied for treatment with DTIC.
